MGO One Seven LLC Purchases 106 Shares of Regeneron Pharmaceuticals, Inc. $REGN

MGO One Seven LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 483 shares of the biopharmaceutical company’s stock after buying an additional 106 shares during the period. MGO One Seven LLC’s holdings in Regeneron Pharmaceuticals were worth $254,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Creative Financial Designs Inc. ADV raised its stake in Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA increased its stake in Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 19 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 19 shares in the last quarter. Cove Private Wealth LLC increased its stake in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares in the last quarter. Finally, Marino Stram & Associates LLC increased its stake in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research note on Monday, August 4th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target for the company. in a research note on Friday, August 1st. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Jefferies Financial Group lifted their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ REGN opened at $578.05 on Monday. The stock has a market capitalization of $61.27 billion, a P/E ratio of 14.57, a P/E/G ratio of 1.80 and a beta of 0.31. The company has a 50-day moving average price of $574.64 and a 200-day moving average price of $562.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,002.69. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same period in the previous year, the company earned $11.56 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.